The ClearCell® Systems

Clearbridge Biomedics (CBB) specialises in novel platforms with applications in oncology research and diagnostics. It is a spin-off from National University of Singapore (NUS) and is also the first incubatee of Clearbridge Accelerator, a Singapore Government (National Research Foundation) backed high-technology incubator. 

Leveraging on novel microfluidic technologies, the ClearCell® Systems and CTChip® adopt a label-free approach for effective detection and isolation of wholly intact Circulating Tumour Cells (CTCs) from patients' blood samples. 

Read on +

 

Disclaimer

Clearbridge BioMedics (hereinafter called 'CBB') disclaims all warranties, both expressed and implied, with respect to the product, including, but not limited to, any implied warranty of merchantability or fitness for a particular purpose. CBB shall not be liable to any person or entity for any medical expenses or any direct, indirect, incidental or consequential damages caused by any use, defect, failure or malfunction of the product, whether a claim for such damages is based upon warranty, contract, tort or otherwise. No person has any authority to bind CBB to any representation or warranty with respect to the product. The exclusions and limitations set out above are not intended to, and should not be construed so as to contravene mandatory provisions of applicable law. If any part or term of this Disclaimer of Warranty is held to be illegal, unenforceable or in conflict with applicable law by court of competent jurisdiction, the validity of the remaining portions of this Disclaimer of Warranty shall not be affected, and all rights and obligations shall be construed and enforced as if this Disclaimer of Warranty did not contain the particular part or term held to be invalid.